Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01345734
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.

Study Details

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

Key Dates

Start date
Sep 1, 2011
Status verified
Dec 2018
Primary completion
Jul 26, 2013
Completion
Jul 26, 2013

Study Design

Enrollment
1,056 participants (actual)

Arms

  • Arm: Liraglutide

Primary Outcome Measure

Incidence of serious adverse drug reactions (SADRs) [ Time Frame: Week 0, week 26 ]

Related Studies